{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=53",
    "query": {
      "condition": "Recurrent Neoplasm",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 9121,
    "total_pages": 913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T06:32:41.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00002637",
      "title": "Biological Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gene-modified tumor cell vaccine therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "1995-01",
      "completion_date": "2001-02",
      "has_results": false,
      "last_update_posted_date": "2013-06-25",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002637"
    },
    {
      "nct_id": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia",
        "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AUTO1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-16",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06173518"
    },
    {
      "nct_id": "NCT02538510",
      "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharynx Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage III Major Salivary Gland Carcinoma",
        "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage III Nasopharyngeal Carcinoma",
        "Stage IV Nasopharyngeal Carcinoma",
        "Stage IVA Major Salivary Gland Carcinoma",
        "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVB Major Salivary Gland Carcinoma",
        "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IVC Major Salivary Gland Carcinoma",
        "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-10-08",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538510"
    },
    {
      "nct_id": "NCT02357810",
      "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Liposarcoma",
        "Metastatic Liposarcoma",
        "Metastatic Osteosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Liposarcoma",
        "Recurrent Osteosarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Oral Topotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2015-03-21",
      "completion_date": "2021-10-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Forest",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357810"
    },
    {
      "nct_id": "NCT00253513",
      "title": "Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "treosulfan",
          "type": "DRUG"
        },
        {
          "name": "allogeneic blood or bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-06",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-01",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 3,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253513"
    },
    {
      "nct_id": "NCT03361306",
      "title": "LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-01-09",
      "completion_date": "2025-02-14",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361306"
    },
    {
      "nct_id": "NCT05425004",
      "title": "Cabozantinib for Patients With Recurrent or Progressive Meningioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningioma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-06-01",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05425004"
    },
    {
      "nct_id": "NCT06266338",
      "title": "Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervix Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2024-03-11",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06266338"
    },
    {
      "nct_id": "NCT03345485",
      "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Soft Tissue Sarcoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Tinostamustine 60mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 60mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 80min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-11-08",
      "completion_date": "2023-03-29",
      "has_results": true,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345485"
    },
    {
      "nct_id": "NCT01302808",
      "title": "Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib plus Romidepsin (8 mg/m^2)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Erlotinib plus Romidepsin (10 mg/m^2)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2021-01-20",
      "last_synced_at": "2026-11-05T06:32:41.285Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01302808"
    }
  ]
}